Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Iqvia (IQV) Stock Price

Press coverage about Iqvia (NYSE:IQV) has trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Iqvia earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 43.8355826528386 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:

IQV has been the subject of a number of research reports. Zacks Investment Research cut shares of Iqvia from a “buy” rating to a “hold” rating in a research report on Friday, January 19th. Mizuho set a $97.00 price objective on shares of Iqvia and gave the company a “hold” rating in a research report on Wednesday, January 24th. SunTrust Banks restated a “hold” rating and issued a $110.00 target price on shares of Iqvia in a research note on Monday, January 22nd. Stifel Nicolaus upgraded shares of Iqvia from a “hold” rating to a “buy” rating and upped their target price for the company from $92.00 to $128.00 in a research note on Friday, October 27th. Finally, TheStreet upgraded shares of Iqvia from a “c+” rating to a “b” rating in a research note on Wednesday, December 13th. Seven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $109.71.

Iqvia (NYSE:IQV) traded up $7.25 during midday trading on Wednesday, reaching $107.31. 373,820 shares of the company’s stock traded hands, compared to its average volume of 1,114,006. Iqvia has a 1 year low of $75.94 and a 1 year high of $110.67. The company has a current ratio of 1.22, a quick ratio of 1.22 and a debt-to-equity ratio of 1.29. The company has a market cap of $20,810.00, a PE ratio of 345.03, a price-to-earnings-growth ratio of 1.34 and a beta of 0.61.

In related news, insider Ari Bousbib sold 46,080 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $101.79, for a total value of $4,690,483.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Cpp Investment Board Private H sold 7,497,807 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $102.00, for a total transaction of $764,776,314.00. The disclosure for this sale can be found here. Insiders sold 8,727,078 shares of company stock valued at $890,124,079 over the last quarter. Insiders own 6.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at

About Iqvia

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Insider Buying and Selling by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with's FREE daily email newsletter.

Leave a Reply